Rapid Personalised,
Breast Cancer Treatment Decision Making.

DigiStain – The UK’s First Breast Cancer
Risk Profiling Technology

A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients.

DigiStain

Patented risk profiling test for hormone
receptor-positive breast cancer patients

Designed With Input from 1500 Oncologists

Developed to serve the needs of oncologist around the world

Risk Actionable Information in Under 1 Hour

A digital solution to cancer grading And Prognosis, faster, quicker and more effective.

Trusted By Prominent Cancer Centres

Successfully validated with >1200 patients in hospitals around England Scotland and Wales

Up to 90% Faster Than the Competition

Unlike other tests requiring weeks to deliver test results,
Digistain renders results in under an hour informing patients and physicians on the likelihood of breast cancer recurrence within the next 5 to 10 years.

Quick, clear, actionable data

Risk Actionable Information in Under 1 Hour

Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.

The MHRA approved Digistain technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.

Delivering radically faster breast cancer treatment decision-making for physicians and patients - reducing actionable treatment decision times from months and weeks to < 1 hour

0 %
Reduction in patient waiting times
0 %
Equivalent to the best in class risk profiling tests used today
0 %
Overall cost reduction through avoided chemotherapy
0 %
Multi-site reproducibility with routinely trained lab technicians

By deploying a well-established analytical technology for chemical analysis with artificial intelligence to assess patient risk for the first time Digistain accelerates clinical workflow with unparalled efficiency

Digistain’s has undergone several clinical trials demonstrating a prognostic score with risk classification equivalent to the best in class genomic tests
The product of15 years of R&D pioneered by respected cancer researchers from Imperial College London and Cancer Research UK
Digistain's Prognostic Score uses a proprietary optical scan of the tumour tocapture a spectral signature (of over 10,000 data points) that is unique to every patient.
Previous
Next
DigiStain
DigiStain

Trusted by Prominent Cancer Hospitals Across The UK

Clinical Evidence - Equivalent to the Gold Standard

Mammaprint
5 years: 0.22
10 years 0.29
Prosigna
5 years: 0.16
10 years 0.24
Digistain
5 years: 0.23
10 years 0.35

In a double-blinded study with over 848 hormone-positive early stage breast cancer patients DigiStain demonstrated equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests

Digistain in Action

Oncolgists say...

Patients say...

Supported by:

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.